Gene Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene Symbol KMT2A
Synonyms ALL-1 | ALL1 | CXXC7 | GAS7 | HRX | HTRX | HTRX1 | MLL | MLL1 | MLL1A | TRX1 | WDSTS
Gene Description KMT2A, lysine methyltransferase 2A, also referred to as MLL, is a transcriptional coactivator that epigenetically regulates gene transcription via methylation and is primarily associated with hematopoietic and embyronic development (PMID: 26161385). KMT2A translocations are frequently observed in specific leukemias including acute myeloid, acute lymphoblastic, and mixed lineage (PMID: 17957188, PMID: 32243611).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04988555 Phase Ib/II DSP-5336 A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation Recruiting USA 1
NCT02487459 Phase I Rivogenlecleucel Rimiducid Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies Withdrawn USA 0
NCT05521087 Phase I Cytarabine + Dexamethasone + Fludarabine + JNJ-75276617 + Pegaspargase + Vincristine Sulfate A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias Not yet recruiting FRA 0
NCT04811560 Phase I JNJ-75276617 A Study of JNJ-75276617 in Participants With Acute Leukemia Recruiting USA | GBR | FRA | ESP | AUS 0
NCT05453903 Phase I JNJ-75276617 + Venetoclax Azacitidine + JNJ-75276617 + Venetoclax Azacitidine + JNJ-75276617 A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies Recruiting USA | ITA | GBR | FRA | ESP | DEU | AUS 0
NCT04065399 Phase Ib/II Revumenib A Study of SNDX-5613 in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) Recruiting USA | NLD | ITA | FRA | ESP | DEU | CAN | AUS 2
NCT03724084 Phase Ib/II Cytarabine + Daunorubicin + Pinometostat Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement Terminated USA 0
NCT03613532 Phase I Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Recruiting USA 0
NCT05886049 Phase I Cytarabine + Daunorubicin + Revumenib Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene Recruiting USA 0
NCT05748171 Phase II Asparaginase + Dexamethasone + Mitoxantrone + Vincristine Sulfate Inotuzumab ozogamicin A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL Recruiting NLD | ITA | FRA | ESP | DEU | BEL | AUT 11
NCT03513484 Phase I Azacitidine + Nintedanib Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia Active, not recruiting USA 0
NCT05327894 Phase III Blinatumomab Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia (Interfant-21) Recruiting NLD | ITA | FRA | DEU | BEL | AUT | AUS 11
NCT05761171 Phase II Cytarabine + Fludarabine Pegaspargase + Prednisone + Vincristine Sulfate Calaspargase pegol-mknl + Prednisone + Vincristine Sulfate Revumenib Cytarabine + Hydrocortisone + Methotrexate Pegaspargase + Prednisolone + Vincristine Sulfate Calaspargase pegol-mknl + Prednisolone + Vincristine Sulfate A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Recruiting USA 0
NCT02828358 Phase II Cytarabine + Hydrocortisone + Leucovorin + Mercaptopurine + Pegaspargase Cyclophosphamide + Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Azacitidine Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Pegaspargase + Thioguanine + Vincristine sulfate liposome Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Thioguanine Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Active, not recruiting USA | CAN | AUS 1
NCT05918913 Expanded access Revumenib Expanded Access Program for SNDX-5613 Available USA 0
NCT06226571 Phase I Cytarabine + Idarubicin + Revumenib Revumenib Cytarabine + Daunorubicin + Revumenib Cytarabine A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias Recruiting USA 0
NCT06284486 Phase II Revumenib + Venetoclax A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib Not yet recruiting USA 0
NCT03114865 Phase Ib/II Blinatumomab + Dexamethasone A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance Active, not recruiting USA 0
NCT06222580 Phase I Gilteritinib + Revumenib SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation Recruiting USA 0
NCT06229912 Phase II Revumenib A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes Not yet recruiting USA 0
NCT04326439 Phase II Cytarabine + Etoposide Cytarabine + Etoposide + Sorafenib Asparaginase Erwinia chrysanthemi + Cytarabine + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin + Sorafenib Cytarabine + Mitoxantrone + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin Asparaginase Erwinia chrysanthemi + Cytarabine Cytarabine + Mitoxantrone AflacLL1901 (CHOA-AML) Terminated USA 0
NCT02141828 Phase I Pinometostat A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene Completed USA | CAN 0
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting USA 0
NCT04659616 Phase I Cytarabine + Pemigatinib Cytarabine + Daunorubicin + Pemigatinib Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia Recruiting USA 0
NCT05735184 Phase I Azacitidine + Venetoclax + Ziftomenib Cytarabine + Daunorubicin + Ziftomenib Venetoclax + Ziftomenib A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML Recruiting USA 0
NCT06287229 Phase Ib/II Brexucabtagene autoleucel Blinatumomab + Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate Blinatumomab + Cyclophosphamide + Dexamethasone + Inotuzumab ozogamicin + Vincristine Sulfate Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab Not yet recruiting USA 0
NCT05848687 Phase Ib/II Bortezomib Dexamethasone Blinatumomab Vorinostat Mercaptopurine Pegaspargase Methotrexate Ziftomenib Mitoxantrone TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II Recruiting USA 0
NCT05326516 Phase I Revumenib A Study of SNDX-5613 in Combination With Chemotherapy in Participants With R/R Acute Leukemia Active, not recruiting USA | CAN 0
NCT06152809 Phase I Aldesleukin + CIML-NK cells + Venetoclax CIML NK Cells With Venetoclax for AML Active, not recruiting USA 0
NCT06001788 Phase I Gilteritinib + Ziftomenib Cytarabine + Ziftomenib Cytarabine + Filgrastim + Fludarabine + Idarubicin + Ziftomenib Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia Recruiting USA 0
NCT03826992 Phase I CPX-351 + Venetoclax Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia Recruiting USA 0
NCT04752163 Phase Ib/II Cyclophosphamide + Cytarabine + Dexamethasone + DS-1594b + Filgrastim + Mesna + Methotrexate + Vincristine Sulfate DS-1594b + Prednisone + Vincristine Sulfate DS-1594b Azacitidine + DS-1594b + Venetoclax Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate + Rituximab DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Completed USA 0
NCT04307576 Phase III Imatinib Blinatumomab Inotuzumab ozogamicin A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting NLD | GBR | FRA | DEU | BEL 9
NCT02419755 Phase II Cytarabine Mercaptopurine Methotrexate Pegaspargase Vorinostat Doxorubicin Bortezomib Dexamethasone Mitoxantrone Prednisone Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies Terminated USA 0
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Terminated USA 0
NCT06177067 Phase I Cytarabine + Hydrocortisone + Methotrexate Azacitidine + Revumenib + Venetoclax Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Not yet recruiting USA 0
NCT01338987 Phase II Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation Completed USA 0
NCT05918692 Phase I BMF-500 A Phase 1, Study of BMF-500 in Adults With Acute Leukemia Recruiting USA 0